SEOUL (TechGenez) – South Korea’s biotechnology sector is preparing to move into the final frontier of medicine by using microgravity in space to discover and produce better drugs.
For decades, Korea’s space programme has focused on rockets and satellites. Now, however, a new generation of biotech companies is turning its attention to space as a laboratory for developing medicines that cannot be made as effectively on Earth.
The reason is simple: in the weightless environment of orbit, proteins and cells can form more perfect, uniform crystals and three-dimensional structures. This gives scientists a clearer picture of how disease-related proteins behave and helps them design more powerful drugs.
Korea Catches Up to Global Leaders
While the United States, the European Union, Japan and China have already run space-based drug research for years, Korea is now playing catch-up. Several companies are taking different routes across the entire drug development chain, from early-stage research to manufacturing.
One of the most ambitious efforts belongs to Space LiinTech, a biotechnology startup. In August 2025, the company became Korea’s first to send a space pharmaceutical research module – the Biomedical Extra-Terrestrial Enclosure, or BEE-PC1 – to the International Space Station aboard a SpaceX Falcon 9 rocket. The automated platform successfully conducted protein crystallization experiments without any astronaut intervention.
In November 2025, Space LiinTech launched BEE-1000, Korea’s first cube satellite, which performed automated experiments on pembrolizumab – the active ingredient in Merck’s blockbuster cancer drug Keytruda.
The startup now plans to send three more platforms into space this year and eight more next year, building a growing fleet of microgravity laboratories.
Major Drugmaker Bets Big on Space
Another player is Boryung, one of Korea’s largest traditional drug companies. In 2022, Boryung invested $60 million in Axiom Space, the company building the first private space station in history. It later created Brax Space, a joint venture with Axiom, to gain exclusive access to the station’s technology in Korea.
Boryung also invested $10 million in Intuitive Machines, the U.S. company that achieved the first private commercial lunar landing in 2024. The Korean drugmaker has signed agreements to develop space healthcare platforms that will use lunar landers and terrain vehicles for biomedical experiments.
In 2022, Boryung launched its Care In Space Challenge, now known as Humans In Space, to identify and fund startups and researchers working on space-based pharmaceutical projects.
A Growing Focus on Antibodies and Organoids
AbTis, a subsidiary of Dong-A ST that specialises in antibody-drug conjugates (ADCs), is taking a more targeted approach. It is testing whether antibodies produced under microgravity can deliver more precise and effective next-generation cancer therapies.
The company designs, optimises and evaluates ADC candidates using antibodies manufactured in space. Researchers believe the higher-quality crystals and more stable structures created in microgravity could dramatically improve the performance of complex biologic drugs.
Industry Experts Call for a National Consortium
Despite these promising efforts, experts say Korea still lacks a coordinated national strategy. Kim Jae-uk, a project manager at the K-Health Medical Innovation Research and Evolution, said Space LiinTech and Boryung are currently moving in parallel without a central body to integrate their work.
He recommends launching a “K-SpaceBio Consortium” to combine forces, share resources and avoid duplication. Kim also calls for a new space biopharmaceutical-dedicated body within the Ministry of Food and Drug Safety and early adoption of space good manufacturing practice (GMP) standards at the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use.
“The gap with the US and Japan could be narrowed,” Kim said. “The willingness of the government, industry and academia is what will determine the speed.”
The Promise of Space Biotechnology
The growing interest in space-based drug research comes at a time when traditional research and development costs are rising sharply. Microgravity offers a unique environment that can accelerate the discovery of better drugs for age-related diseases, cancer and infectious conditions.
As Korea prepares to catch up to global leaders, the country’s biotech sector is positioning itself at the forefront of a new era of medicine – one that may depend as much on the vacuum of space as on Earth-bound laboratories.
Conclusion
Korea’s biotechnology companies are taking a bold step into the final frontier of drug development. From protein crystals grown in microgravity to organoids and stem cells grown in space, the country is exploring how the unique conditions of orbit can unlock more powerful and effective medicines. With the right coordination and investment, Korean firms could become key players in the global race to turn the void into a new era of healing.
